Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CMP-002

Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by CAMP4 Therapeutics

Phase 1/2 Most advanced trial
CAMP Developer
1 Registered trials

What is CMP-002?

CMP-002 is an antisense oligonucleotide administered by intrathecal injection. It is studied in nervous system diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (Antisense oligonucleotide)
Mechanism
Gene silencing
Therapy area
Neurology
Developer
CAMP4 Therapeutics Corporation (CAMP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07935135 Phase 1/2 Nervous System Disease Not yet recruiting CAMP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Nervous System Disease

More from CAMP4 Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the CAMP page.

Follow CAMP, the company behind CMP-002

See CAMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CAMP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.